Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan-Feb;22(1):23-6.
doi: 10.1097/PPO.0000000000000168.

Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma

Anna Alperovich  1 , Anas Younes
Affiliations
Review

Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma

Anna Alperovich et al. Cancer J. 2016 Jan-Feb.

Abstract

The expression of CD30 receptors is one of the defining characteristics of the malignant Reed-Sternberg cells of Hodgkin lymphoma (HL). CD30 is rarely expressed by normal cells and is rapidly internalized, making it an ideal therapeutic target for monoclonal antibodies and for antibody-drug conjugates. Brentuximab vedotin is the first antibody-drug conjugate to be approved by regulatory agencies for the treatment of patients with relapsed HL, with a single-agent response rate of 75%. In this review article, we discuss the current and ongoing development of brentuximab vedotin in patients with relapsed and newly diagnosed HL.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Brentuximab vedotin mechanism of action. As an antibody for CD30, BV then enters cell via endocytosis. In the lysosome, the cytotoxin monomethyl auristatin E gets released. When MMAE enters the nucleus, it disrupts mitosis at the microtubulin level, causing apoptosis.
Figure 2
Figure 2
Response rate of brentuximab vedotin used as monotherapy and combination therapy in patients that are refractory or relapsed after frontline therapy, before autosomal stem cell transplant.
See this image and copyright information in PMC

References

    1. Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85(1):1–14. - PubMed
    1. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. The New England journal of medicine. 2010;363(19):1812–1821. - PubMed
    1. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(18):2183–2189. - PMC - PubMed
    1. Gopal AK, Ramchandren R, O'Connor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012;120(3):560–568. - PMC - PubMed
    1. Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. The Lancet Oncology. 2013;14(13):1348–1356. - PubMed

MeSH terms